Advanced Cervical Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Advanced cervical cancer, also known as stage III or stage IV cancer of the cervix, has progressed beyond the early stages and has spread to nearby tissues or distant organs. Cervical cancer's primary cause is persistent infection with high-risk types of HPV. Human papillomavirus infection is a sexually transmitted virus that can lead to changes in cervical cells over time, eventually leading to cancer in some cases. Cervical cancer occurs most often in people over age 30. Advanced cervical cancer signs and symptoms may include Abnormal vaginal bleeding, especially between periods, after intercourse, or after menopause, Pelvic pain or pain during intercourse, Unexplained weight loss, and fatigue. Swelling of the legs or lower back pain if cancer has spread to the lymph nodes or other organs, Urinary problems, or bowel issues if the cancer presses on nearby structures. Several risk factors increase the likelihood of developing cervical cancer, including - Persistent HPV (Human Papillomavirus) infection, Smoking, Weak immune system, Long-term use of birth control pills, Multiple sexual partners, Early sexual activity, and Family history of cervical cancer. Treatments for advanced cervical cancer include chemotherapy, radiation therapy, targeted drugs, and surgery. The primary treatment for later stages of cervical cancer is a combination of radiation and chemotherapy. Chemo alone is often used to treat advanced cervical cancer. Stage 4A cervical cancer treatment is usually a combination of radiotherapy and chemotherapy (chemoradiotherapy). Cervical cancer's 5-year relative survival rate is 60% when it has spread to nearby tissues, organs, or regional lymph nodes. The 5-year close survival rate is 19% when cervical cancer has spread to a distant part of the body.
·
Cervical cancer incidence in the USA was
estimated to be 7.7 per 100,000 women annually.
Thelansis’s “Advanced Cervical Cancer
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2022 To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Advanced Cervical Cancer treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
KOLs insights
of Advanced Cervical Cancer across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Advanced Cervical Cancer Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment